Wireframe anatomical render of a human brain, heart and spine on a black background
PUNE, INDIA
CLINICAL AI RESEARCH
PIPELINE
NETRA · CPI · INDIRA · NFAD
DESIGNED FOR
CDSCO · EU MDR · FDA
REVIEW
STATUS
ALL RESEARCH-STAGE

AlgoMD — Algorithms built for medicine

AlgoMD is a research company building clinical algorithms for the patients existing tools were not built on — starting with India.
Every algorithm is research-stage and not available for clinical use.
AlgoMD builds clinical AI for regulatory reviewassembled deliberately and in sequence, toward global diagnostic integration.

AlgoMD is building a new foundation for clinical AI — trained on the populations it serves, documented in public, and taken through regulatory review in sequence.

The gap

Most clinical risk tools used in India were derived from European and North American patients. SCORE2, the European heart-risk model, was built on 677,684 people with no South Asian representation, and INFLUENCE 3.0 for breast cancer on 36,000 Dutch patients.

The approach

Take each field’s benchmark tool apart, rebuild it on Indian data with India-specific variables, publish the model card, and take it through CDSCO review — then carry the same discipline to EU MDR and the FDA.

Building deliberately and in sequencetoward CE marking, FDA clearance, and global diagnostic integration.

The pipeline

Four algorithms, each labelled with the stage it has actually reached. None is available for clinical use.

Full pipeline ↗
Retrospective research
Domain
[Domain to be added]

[One-sentence indication to be added.] Model card in preparation.

Stage 1 of 4 · Research
Target: [To be added]
NETRA
[Full name to be added]
Pipeline entry↗
Data acquisition
Domain
Cardiology — Cardiovascular risk

Cardiovascular risk estimation for South Asian patients, rebuilt from SCORE2 and the HEART Score with India-specific variables.

Stage 1 of 4 · Research
Target: CDSCO Class B/C
CPI
CardioPredict-India
Overview↗
Data acquisition
Domain
Oncology — Breast cancer

5- and 10-year locoregional recurrence risk in non-metastatic breast cancer, re-derived for Indian patients.

Stage 1 of 4 · Research
Target: CDSCO Class C
INDIRA
Locoregional Recurrence Algorithm
Overview↗
Retrospective research
Domain
Neurology — Alzheimer’s disease

Multimodal research model estimating amyloid and cognitive-decline risk in mild cognitive impairment.

Stage 1 of 4 · Research
Target: EU MDR Class IIa
NFAD
NeuroFusion-AD
Overview↗
Four
•  The thesis

Each step funds the next.

AlgoMD’s Indian SaMD portfolio is not a detour from NFAD — it is the strategic architecture that makes NFAD achievable.

CDSCO Class B/C approval is faster and more accessible to a lean company than EU MDR Class IIa, making it the correct first milestone. Everything built for it — the ISO 13485 QMS, IEC 62304 lifecycle files, and clinical evaluation methodology — transfers directly to an EU MDR technical file. Each submission is a rehearsal for the Notified Body review.

4
Algorithms in the research pipeline
0
Cleared for clinical use. Every algorithm here is research software.

Latest

All insights ↗Lab Notes ↗
Introducing AlgoMD
Article · 9 November 2026
The data gap: why risk tools built elsewhere misjudge Indian patients

Most heart-risk and breast-cancer tools used in Indian clinics were derived from European patients. What that means, and what it takes to fix.

Read article ↗
Six•  Work with us

Help move an algorithm to its next stage.

Clinicians, data holders, industry, researchers and future colleagues: one form, read by the founder, answered within 48 hours.

Clinical collaborationData partnershipIndustry partnershipResearch collaborationCareers
Work with us